D'Alessandria C - Search Results

1

Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.

Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, Sandhu S, Kratochwil C, Esfandiari R, Tauber R, Zeldin A, Rathke H, Armstrong WR, Robertson A, Thin P, D'Alessandria C, Rettig MB, Delpassand ES, Haberkorn U, Elashoff D, Herrmann K, Czernin J, Hofman MS, Fendler WP, Eiber M. Gafita A, et al. Lancet Oncol. 2021 Aug;22(8):1115-1125. doi: 10.1016/S1470-2045(21)00274-6. Epub 2021 Jul 8. Lancet Oncol. 2021. PMID: 34246328 Free article.

2

Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.

Heck MM, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester HJ, Gschwend JE, Schwaiger M, Tauber R, Eiber M. Heck MM, et al. J Urol. 2016 Aug;196(2):382-91. doi: 10.1016/j.juro.2016.02.2969. Epub 2016 Mar 8. J Urol. 2016. PMID: 26964917

3

Radiation Dosimetry for ¹⁷⁷Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions.

Okamoto S, Thieme A, Allmann J, D'Alessandria C, Maurer T, Retz M, Tauber R, Heck MM, Wester HJ, Tamaki N, Fendler WP, Herrmann K, Pfob CH, Scheidhauer K, Schwaiger M, Ziegler S, Eiber M. Okamoto S, et al. J Nucl Med. 2017 Mar;58(3):445-450. doi: 10.2967/jnumed.116.178483. Epub 2016 Sep 22. J Nucl Med. 2017. PMID: 27660138 Free article.

4

The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for ¹⁷⁷Lu-Labeled PSMA Peptides.

Begum NJ, Thieme A, Eberhardt N, Tauber R, D'Alessandria C, Beer AJ, Glatting G, Eiber M, Kletting P. Begum NJ, et al. J Nucl Med. 2018 Jun;59(6):929-933. doi: 10.2967/jnumed.117.203505. Epub 2018 Feb 1. J Nucl Med. 2018. PMID: 29419479 Free article.

5

Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis.

Pfob CH, Eiber M, Luppa P, Maurer F, Maurer T, Tauber R, D'Alessandria C, Feuerecker B, Scheidhauer K, Ott A, Heemann U, Schwaiger M, Schmaderer C. Pfob CH, et al. EJNMMI Res. 2018 Feb 27;8(1):17. doi: 10.1186/s13550-018-0370-z. EJNMMI Res. 2018. PMID: 29488080 Free PMC article.

6

Modeling and Predicting Tumor Response in Radioligand Therapy.

Kletting P, Thieme A, Eberhardt N, Rinscheid A, D'Alessandria C, Allmann J, Wester HJ, Tauber R, Beer AJ, Glatting G, Eiber M. Kletting P, et al. J Nucl Med. 2019 Jan;60(1):65-70. doi: 10.2967/jnumed.118.210377. Epub 2018 May 10. J Nucl Med. 2019. PMID: 29748236 Free article.

7

Early Experience of Rechallenge ¹⁷⁷Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer.

Gafita A, Rauscher I, Retz M, Knorr K, Heck M, Wester HJ, D'Alessandria C, Weber WA, Eiber M, Tauber R. Gafita A, et al. J Nucl Med. 2019 May;60(5):644-648. doi: 10.2967/jnumed.118.215715. Epub 2018 Nov 15. J Nucl Med. 2019. PMID: 30442756 Free article.

8

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with ¹⁷⁷Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.

Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, Schwaiger M, Knorr K, Eiber M. Heck MM, et al. Eur Urol. 2019 Jun;75(6):920-926. doi: 10.1016/j.eururo.2018.11.016. Epub 2018 Nov 22. Eur Urol. 2019. PMID: 30473431

9

The effect of attenuation map, scatter energy window width, and volume of interest on the calibration factor calculation in quantitative ¹⁷⁷Lu SPECT imaging: Simulation and phantom study.

Karimi Ghodoosi E, D'Alessandria C, Li Y, Bartel A, Köhner M, Höllriegl V, Navab N, Eiber M, Li WB, Frey E, Ziegler S. Karimi Ghodoosi E, et al. Phys Med. 2018 Dec;56:74-80. doi: 10.1016/j.ejmp.2018.11.009. Epub 2018 Nov 29. Phys Med. 2018. PMID: 30527092

10

Exceptional 4-year response to ¹⁷⁷Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.

Gafita A, Wang H, Tauber R, D'Alessandria C, Weber WA, Eiber M. Gafita A, et al. Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2212-2213. doi: 10.1007/s00259-019-04410-8. Epub 2019 Jul 4. Eur J Nucl Med Mol Imaging. 2019. PMID: 31273434 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters